Gubra A/S (FRA:PI3)
Germany · Delayed Price · Currency is EUR | Market Cap | 634.99M -31.5% |
| Revenue (ttm) | 36.25M -89.7% |
| Net Income | -24.38M |
| EPS | -1.49 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 63.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 75 |
| Open | 39.12 |
| Previous Close | 39.26 |
| Day's Range | 38.24 - 39.12 |
| 52-Week Range | 37.18 - 73.15 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 3, 2027 |
About Gubra
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinfor... [Read more]
News
Gubra A/S at Morgan Stanley Global Healthcare Conference Transcript
Gubra A/S at Morgan Stanley Global Healthcare Conference Transcript
Gubra Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The discussion highlighted a robust pipeline with two phase II obesity assets partnered with major pharma, a promising proprietary UCN2 program, and a resilient CRO business. Strategic focus includes expanding beyond obesity, leveraging internal capabilities, and maximizing asset value before partnering.
Gubra Slides: Investor presentation
Gubra has posted slides in relation to its latest quarterly earnings report, which was published on August 25, 2026.
Gubra Quarterly report: Q2 2026
Gubra has published its Q2 2026 quarterly earnings report on August 24, 2026.
Gubra Slides: Q2 2026
Gubra has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 24, 2026.
Gubra Earnings Call Transcript: Q2 2026
Strong H1 2026 performance included major R&D milestones, CRO revenue growth of 11%, and a return to profitability. Guidance for 2026 remains unchanged, with robust clinical progress and a positive outlook for both biotech and CRO segments.
Gubra Quarterly report: Q2 2026
Gubra has published its Q2 2026 quarterly earnings report on August 20, 2026.
Gubra Slides: Q2 2026
Gubra has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 20, 2026.
Gubra Slides: Investor presentation
Gubra has posted slides in relation to its latest quarterly earnings report, which was published on June 19, 2026.
Gubra Earnings release: Q1 2026
Gubra released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Gubra Slides: Q1 2026
Gubra has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Gubra Earnings Call Transcript: Q1 2026
Q1 2026 saw strong biotech pipeline momentum, facility expansion, and key leadership hires. Revenue improved due to Amylyx milestone, while CRO showed sequential growth but faces ongoing market volatility. Two partnered assets advance to phase II in 2026.
Gubra Earnings release: Q1 2026
Gubra released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Gubra Slides: Q1 2026
Gubra has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Gubra Slides: Investor presentation
Gubra has posted slides in relation to its latest quarterly earnings report, which was published on April 15, 2026.
Gubra Slides: Investor presentation
Gubra has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
Gubra Annual report: Q4 2025
Gubra has published its Q4 2025 annual report on March 3, 2026.
Gubra Slides: Q4 2025
Gubra has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 3, 2026.
Gubra Earnings Call Transcript: Q4 2025
Record 2025 results driven by the AbbVie deal, with revenue of DKK 2.6 billion and net profit of DKK 1.7 billion. CRO growth slowed due to US biotech headwinds but is expected to rebound in 2026. Pipeline expansion and new ventures are set to drive future growth.
Gubra Annual report: Q4 2025
Gubra has published its Q4 2025 annual report on February 27, 2026.
Gubra Slides: Q4 2025
Gubra has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 27, 2026.
Gubra Slides: Investor presentation
Gubra has posted slides in relation to its latest quarterly earnings report, which was published on December 18, 2025.
Gubra Earnings release: Q3 2025
Gubra released its Q3 2025 earnings on November 7, 2025, summarizing the period's financial results.
Gubra Slides: Q3 2025
Gubra has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 7, 2025.
Gubra Earnings Call Transcript: Q3 2025
Record revenue and margins were achieved, driven by milestone deals and strong Discovery & Partnerships performance, despite a 5% CRO revenue decline due to macroeconomic headwinds. UCM2 and ABBV-295 programs advanced, with clinical trials planned and a major out-licensing deal completed.